Neil Perry is Content Director for Outlook Publishing.
- Content Director
Share
Novo Nordisk and Amazon Web Services (AWS) have formed a strategic partnership focused on using artificial intelligence (AI) and cloud technologies to accelerate drug discovery, increase research and development (R&D) productivity and support the development of future medicines.
Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner as the healthcare company looks to modernise its technology infrastructure and reduce drug development timelines.
As part of the agreement, the companies have established an AI co-innovation hub within Novo Nordisk’s existing facility in London.
The hub brings together AWS engineers, AI specialists and applied scientists with Novo Nordisk R&D teams. They will combine AWS AI technologies with Novo Nordisk’s data and scientific insights to help shorten the process from identifying a drug target to administering a first human dose.
Mike Doustdar, president and CEO of Novo Nordisk, said: “Partnering with AWS is about making AI a driver of innovation across Novo Nordisk. By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.”
Maziar Mike Doustdar President and Chief Executive Officer (CEO)
Cloud Technology Connects Research and Clinical Data
The partnership combines Novo Nordisk’s therapeutic knowledge across chronic diseases with AWS’s cloud infrastructure, AI services and life sciences technologies.
Novo Nordisk plans to use Amazon Bio Discovery and Amazon Bedrock to identify drug targets, support the design of new therapies and connect genomic, imaging and clinical data and connecting these datasets could enable findings from early-stage research to help shape clinical trial design.
Novo Nordisk will also use Amazon Bedrock AgentCore to deploy AI agents aimed at improving operational efficiency.
The healthcare company said its existing collaboration with AWS has already reduced clinical documentation time and provided productivity tools to more than 25,000 employees.
AI and Cloud Infrastructure Support Next-Generation Medicines
The expanded agreement is intended to provide secure technology infrastructure for developing new therapies and scaling research findings across different therapeutic areas.
Matt Garman, CEO, AWS, said: “Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster. Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas.”
Matt Garman, CEO, AWS
The partnership builds on an existing relationship between the companies and forms part of Novo Nordisk’s wider use of technology to support its research, development and operations.
Novo Nordisk also works with other Amazon businesses supporting the healthcare sector, including Amazon Pharmacy, Amazon Ads and Amazon One Medical, covering areas including the marketing and delivery of therapies to patients.
This article was produced by the editorial team at North America Outlook and published as part of the Outlook Publishing global network of B2B industry magazines.
Outlook Publishing delivers industry insights, company stories, and sector coverage across manufacturing, mining, construction, healthcare, supply chains, food production, and sustainability.
North America Outlook provides ongoing coverage of organisations and developments shaping industries across North America.
